GlobeNewswire

Taking on Calendar Spam, Scheduling Developers Organization CalConnect Collaborates with Messaging Anti-Abuse M3AAWG

Dela

MCKINLEYVILLE, Calif. and SAN FRANCISCO, April 05, 2018 (GLOBE NEWSWIRE) -- Recognizing that calendar spam is a growing exploitation channel, CalConnect and the global anti-abuse association M3AAWG have joined forces to develop new methods to protect end-users from unsolicited and malicious event notices.  The new liaison between the scheduling developers' organization and the Messaging, Malware and Mobile Anti-Abuse Working Group will accelerate industry efforts to develop techniques that block invites to fake events and other malicious notices on popular calendaring platforms.

Calendar spam is a new form of abuse that takes advantage of the application layer across multiple technologies, including scheduling, calendaring and messaging systems. For example, users have received fraudulent emails impersonating well-known brands that include calendar invites to special "discount" events.  As is the case with email spam, calendar spam can be used for malicious purposes such as phishing or to deliver malware payloads.

CalConnect (The Calendaring and Scheduling Consortium) also has established a new technical committee, TC CALSPAM, to better protect users from calendar system abuse. The committee aims to understand the current and potential use of calendar systems as a vector for delivering undesired information and will provide current information and guidelines on the topic to CalConnect and M3AAWG participants.

"Calendaring is an intimate part of everyone's lives. Calendar spam is particularly unsettling because the abuse directly pops up on a person's calendar.  It's personally disruptive and especially disturbing," said Thomas Schäfer, 1&1's Head of Technical Site Management who chairs TC CALSPAM.

Differs from Other Abuse  Schemes

CalConnect and M3AAWG will develop the measures and best practices for developers and system operators to ensure legitimate usage of their platforms.  The collaborative effort is important because calendar spam is unique as an abuse vector in a number of ways:

  • Calendar spam, unlike email, can be placed chronologically anywhere in a calendar - in the past or the future, not just the present - making it difficult to detect at the time of delivery.
  • Spam meeting invitations can be automatically added to calendars without the users' consent with notifications sent to all their devices. These invitations are not only difficult to find but, in some cases, there is no way for the user to remove these events short of deleting the entire calendar.
  • Calendar events and meeting invitations do not yet carry the rich provenance, i.e., the detailed header information that is included in email, making it difficult to ascertain where and when events originated and where they were delivered.
  • Calendar events often contain notifications or alarms that are propagated across a user's many desktop and mobile calendaring clients, exacerbating the problem.

M3AAWG Executive Director Jerry Upton said, "Calendar spam has shown itself to be a new but rapidly maturing vector for spammers.  As we've seen in addressing other abuse issues in M3AAWG, cross-domain problems like this require input from experts in multiple disciplines and collaborating with CalConnect and their subject matter is the most direct route to combatting this evolving threat."

Call for Industry Participation

The reciprocal membership agreement between the two organizations became effective in February and allows the calendaring and scheduling developers, vendors and service providers in CalConnect and the messaging and email authentication experts in M3AAWG to share information and work.  CalConnect members participated in the M3AAWG 42nd General Meeting in San Francisco in February, kicking off the joint work on applicable anti-abuse methodologies.  The 43rd M3AAWG General Meeting will be held June 4-7 in Munich, Germany.

CalConnect President Rutger Geelen said, "We recognize that calendar spam is a real threat and a growing problem. First and foremost, we endeavor to protect users against such abuse. Since event and meeting invitations are often delivered via email, it makes sense to collaborate with the messaging identity and authentication experts at M3AAWG in our effort to return full control of collaboration and communications to the end users themselves."

Organizations interested in joining the CalConnect calendar spam committee should contact CalConnect Executive Director Dave Thewlis at dave.thewlis@calconnect.org or CalConnect Director of External Relations Ronald Tse at ronald.tse@calconnect.org

About The Calendaring and Scheduling Consortium (CalConnect)

CalConnect, The Calendaring and Scheduling Consortium, CalConnect, is a not-for-profit organization advancing the state of interoperable calendaring, scheduling and digital contacts. Founded in 2004 as a partnership between vendors and users of calendaring and scheduling tools and technologies, its membership includes some of the world's largest software companies as well as small startups. Virtually every important calendaring-related standard since 2004 has been authored, edited, and/or co-edited by members of a CalConnect Technical Committee. http://www.calconnect.org.

About the Messaging, Malware and Mobile Anti-Abuse Working Group (M 3 AAWG)

The Messaging, Malware and Mobile Anti-Abuse Working Group (M3AAWG) is where the industry comes together to work against bots, malware, spam, viruses, denial-of-service attacks and other online exploitation. M3AAWG (www.m3aawg.org) members represent more than one billion mailboxes from some of the largest network operators worldwide. It leverages the depth and experience of its global membership to tackle abuse on existing networks and new emerging services through technology, collaboration and public policy, and works to educate global policy makers on the technical and operational issues related to online abuse and messaging.

Media Contacts:

Ronald Tse, Director, External Relations, ronald.tse@calconnect.org
CalConnect (The Calendaring and Scheduling Consortium), https://www.calconnect.org

Linda Marcus, APR, Astra Communications, +1-714-974-6356 (U.S. Pacific), LMarcus@Astra.cc 
M3AAWG (Messaging, Malware and Mobile Anti-Abuse Working Group), https://www.m3aawg.org




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Messaging Anti-Abuse Working Group (M3AAWG) via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Arcoma AB: Arcoma presenterar på Redeye Life Science Day den 21:a november16.11.2018 12:53Pressmeddelande

16 November Den 21 november presenterar Jesper Söderqvist, VD på Arcoma, den senaste utvecklingen i Arcoma på Haymarket by Scandic i Stockholm. Presentationen "Arcoma, ett tillväxtbolag i en växande marknad" hålls klockan 13:00 och kan följas i livesändning på redeye.se/live/lsday-2018. Presentationen kommer även i efterhand att finnas tillgänglig på www.redeye.se/live/ls-day-2018 samt på Bolagets sida i Redeye Universe (redeye.se/company/Arcoma) Om Arcoma Arcoma, med lång erfarenhet av branschen, är en ledande leverantör av integrerade digitala röntgensystem med hög kvalitet och avancerad teknik. Arcomas produkter erbjuder den senaste digitala bildtekniken kombinerat med tekniskt avancerade rörliga positioneringssystem, vilket tillsammans med ergonomisk skandinavisk design, erbjuder kunden kompletta, konfigurerbara och funktionella digitala röntgensystem. Bolagets produkter säljs via återförsäljare samt via OEM-kunder och det finns idag över 3 500 av Arcomas röntgensystem installerade

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum